AbbVie News Center - News
WEB2 days ago — Get News Alerts by Email September 26, 2024 AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
AbbVie to Acquire ImmunoGen, including its Flagship Cancer
WEBNov 30, 2023 — Some statements in this news release, including those relating to the proposed acquisition of ImmunoGen by AbbVie, are, or may be considered, forward-looking statements. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements.
AbbVie to Acquire Landos Biopharma, Further Strengthening its
WEBMar 25, 2024 — The definitive proxy statement will be sent to Landos' stockholders in connection with the proposed transaction. This news release is not a substitute for the proxy statement or any other document that may be filed by Landos with the SEC.
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
WEBDec 6, 2023 — This news release may be deemed solicitation material in respect of the proposed acquisition of Cerevel. A special shareholder meeting will be announced soon to obtain Cerevel shareholder approval in connection with the proposed acquisition.
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
WEBFeb 2, 2024 — Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense ; Delivers Full-Year Net Revenues of $54.318 Billion, a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational Basis
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
WEBFeb 12, 2024 — AbbVie updates previously issued 2024 first-quarter adjusted diluted EPS guidance range from $2.30-$2.34 to $2.26-$2.30 which now includes a $0.04 per share dilutive impact related to the ImmunoGen acquisition. NORTH CHICAGO, Ill., Feb. 12, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ...
AbbVie Completes Transformative Acquisition of Allergan
WEBMay 8, 2020 — Mr. Freyman recently served on the Allergan Board of Directors. Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total consideration of $193.23 per Allergan share (based on the closing price of AbbVie's common stock of …
AbbVie Announces Appointment of Robert A. Michael as Chief …
WEBFeb 20, 2024 — Transition will occur on July 1, 2024. NORTH CHICAGO, Ill., Feb. 20, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr.
Press Kits - AbbVie News Center
WEBStay up to date on recent news, articles, and more by subscribing to email alerts for one or more of our news topics. Learn more
AbbVie and Tentarix Announce Collaboration to Develop ... - News
WEBFeb 22, 2024 — AbbVie Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or …